Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Feb 1;138(3):525-32.
doi: 10.1002/ijc.29431. Epub 2015 Jan 28.

Clinical Significance of Cancerous Inhibitor of Protein Phosphatase 2A in Human Cancers

Affiliations
Free article
Review

Clinical Significance of Cancerous Inhibitor of Protein Phosphatase 2A in Human Cancers

Anchit Khanna et al. Int J Cancer. .
Free article

Abstract

Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A), a recently identified oncogene, has emerged as a potential drug target for a range of different tumor types. High CIP2A expression has been reported in almost all solid organ cancers and in some hematological tumors and is associated with high grade and poor prognosis. Notably, high CIP2A expression is determined in over 70% of tumor patient samples in the majority of human cancers. High expression of CIP2A has also been proposed as a useful biomarker that predicts therapeutic response to chemotherapeutics such as Bortezomib, Erlotinib, Checkpoint Kinase 1 inhibitors and pro-senescence based therapies. In this review, we highlight, critically evaluate and discuss the ambiguity in CIP2A's prognostic role in different human cancers and its role in modulating response and resistance to chemotherapeutics.

Keywords: CHK1; CIP2A; DNA-PKc; MYC; P53; PP2A; biomarker; drug resistance; patient stratification; personalized medicine; prognostic role; tumor grade.

Similar articles

See all similar articles

Cited by 17 articles

See all "Cited by" articles

Publication types

LinkOut - more resources

Feedback